



# **Pictilisib**

Catalog No: tcsc0081

9
Ţ

### **Available Sizes**

Size: 10mg

Size: 50mg

Size: 100mg

Size: 200mg

Size: 500mg

Size: 1g



# **Specifications**

CAS No:

957054-30-7

Formula:

 ${\rm C_{23}H_{27}N_{7}O_{3}S_{2}}$ 

**Pathway:** 

PI3K/Akt/mTOR; Autophagy

**Target:** 

PI3K; Autophagy

**Purity / Grade:** 

>98%

**Solubility:** 

DMSO : ≥ 29 mg/mL (56.46 mM)

**Alternative Names:** 

GDC-0941





#### **Observed Molecular Weight:**

513.64

## **Product Description**

Pictilisib (GDC-0941) is a potent inhibitor of **PI3Kα/δ** with an **IC**<sub>50</sub> of 3 nM, with modest selectivity against p110 $\beta$  (11-fold) and p110 $\gamma$  (25-fold).

IC50 & Target: IC50: 3 nM (PI3Kα), 3 nM (PI3Kδ)<sup>[5]</sup>

*In Vitro:* Pictilisib (GDC-0941) and docetaxel reduce tumor cell viability by 80% or greater in the breast cancer cell lines than single-agent treatment. GDC-0941 inhibits Akt phosphorylation and downstream targets of Akt signaling such as pPRAS40 and pS6 in Hs578T1.2 (PI3Kα wild-type), MCF7-neo/HER2 (PI3Kα-mutant), and MX-1 (PTEN-null) tumor models. Pictilisib (GDC-0941) decreases the time of docetaxel-induced mitotic arrest prior to apoptosis<sup>[1]</sup>. Pictilisib (GDC-0941) shows a high efficacy of antitumor activity in two gefitinib-resistant non-small cell lung cancer (NSCLC) cell lines, A549 and H460. Pictilisib (GDC-0941) is highly efficacious in combination with U0126 in inducing cell growth inhibition, G0-G1 arrest and cell apoptosis. H460 cells with activating mutations of PIK3CA are relatively more sensitive to Pictilisib (GDC-0941) than A549 cells with wild-type PIK3CA<sup>[3]</sup>. Pictilisib (GDC-0941) reduces PI3K pathway activity in both cell lines, illustrated by decreased pAK. Pictilisib (GDC-0941) significantly reduces secreted VEGF detected in the medium after hypoxic/anoxic exposure in all cells<sup>[4]</sup>.

*In Vivo:* Pictilisib (GDC-0941) (150 mg/kg, p.o.) leads to tumor stasis in MCF7-neo/HER2-bearing animals model. Pictilisib (GDC-0941) and docetaxel result in tumor regressions during the treatment period leading to enhanced antitumor responses<sup>[1]</sup>. Tumours in the Pictilisib (GDC-0941)-treated mice show a marked non-linear shrinkage, and when the Pictilisib (GDC-0941) treatment ceased, the tumours in the test cohort mice grow again<sup>[2]</sup>. Pictilisib (GDC-0941) (25 or 50 mg/kg) reduces tumor growth and PI3K and HIF-1 pathway activity in eGFP-FTC133 tumor-bearing mice<sup>[4]</sup>.

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!